AI in Clinical Trials: Why Technology Still Needs a Human Touch
- Shawn Thomas
- 8 minutes read
Artificial intelligence is moving from an experimental technology to a practical tool across clinical research. AI in clinical trials can help identify potential participants, review complex eligibility criteria, analyze large datasets, support safety monitoring, and reduce repetitive work. Yet clinical research ultimately depends on people making informed decisions about their health. The most useful question, therefore, is not whether AI should replace human involvement. It is where technology can improve speed and precision, and where knowledgeable human interaction remains essential. That balance is becoming increasingly important as sponsors and study teams introduce AI into recruitment and trial operations.
AI in Clinical Trials Can Make Recruitment More Efficient
Finding potentially eligible participants is one of the clearest applications of AI. Traditional recruitment may require teams to compare medical records against lengthy inclusion and exclusion criteria, a process that can consume considerable staff time before anyone contacts a patient.
AI can help narrow that workload. A 2026 scoping review and meta-analysis covering 121 studies found strong performance for AI-assisted patient screening and eligibility identification, although results varied by application.
As an example, a large language model-based system designed to match patients with clinical trials, was able to filter large numbers of trials into more relevant candidate lists. In a user study, researchers using the system reduced patient-screening time by 42.6 percent compared with conventional approaches.
That is an important distinction. The technology did not need to become the recruiter. It reduced the amount of information a person had to work through.
This is where AI in clinical trials can provide significant value: finding patterns, organizing information, identifying likely matches, and helping teams focus their attention where it is most useful.
AI Can Support More Than Patient Matching
Recruitment is only one opportunity. AI models are being studied across clinical development for tasks including predicting outcomes, analyzing real-world and digital health data, identifying disease-progression patterns, assessing operational and safety risks, and helping researchers work with increasingly large datasets.
Safety monitoring is another example. Researchers have investigated natural language processing and AI methods to assist with classification of adverse-event information, a task traditionally dependent on manual clinical review.
AI is also beginning to move into formally recognized drug-development workflows. In December 2025, the FDA qualified its first AI-based drug development tool. The system assists pathologists with scoring liver biopsy images in MASH clinical trials. Importantly, it does not make the final decision. Pathologists remain responsible for interpreting the images and can accept or reject the AI-generated results.
That human-in-the-loop structure offers a useful model for clinical research more broadly: let technology accelerate analysis while keeping accountable professionals responsible for consequential judgments.
Recruitment Still Requires Conversation
The limits of automation become especially clear when a potential participant moves from being a data match to being a person considering a clinical trial.
An algorithm may identify someone whose records appear to fit a protocol. It cannot assume that the person understands the study, is comfortable participating, can manage the visit schedule, has concerns about randomization, or is ready to discuss sensitive medical history.
Human interaction can matter during that transition. In one randomized study, telephone follow-up resulted in clinical trial enrollment of 12.3 percent of contacted individuals compared with 7.4 percent among those receiving mail follow-up. A broader review of recruitment interventions also found evidence that telephone reminders could improve recruitment in some settings.
More recent evidence suggests the answer is not simply “phone good, automation bad.” A 2026 analysis of recruitment communication found that combining email and telephone outreach improved the likelihood of reaching a definitive recruitment outcome, while repeated calling eventually produced diminishing returns.
That points toward an omnichannel model rather than a technology-versus-people model.
Automated communication can efficiently confirm receipt, send reminders, collect straightforward information, or identify the right time for follow-up. A trained nurse or other qualified study-support professional can then handle situations that require discussion, clarification, empathy, or clinical judgment.
Human Oversight Also Protects Against AI’s Weaknesses
Efficiency is not the only consideration when introducing AI into clinical trials.
AI systems depend on the data, assumptions, and workflows used to build and deploy them. Reviews of AI-based clinical trial recruitment have identified concerns including privacy, data security, transparency, selection bias, discrimination, and limited validation.
Those risks can affect who is identified for a study as well as who might inadvertently be overlooked. AI bias can arise from computational systems, human decisions, and broader organizational or societal processes. Bias therefore cannot always be solved by improving an algorithm alone.
The regulatory direction reflects the same principle. FDA guidance on AI used to support drug-development decisions emphasizes establishing credibility for the model’s specific context of use rather than treating an AI system as universally reliable.
A 2026 review of AI readiness in clinical trial operations similarly found that the strongest evidence currently concerns patient-trial matching and eligibility assessment, but even those applications were generally supported by retrospective or simulated evaluations rather than the highest levels of real-world operational evidence. The authors highlighted human accountability, validation, auditability, and ongoing monitoring as important elements of responsible adoption.
The Best Model Is Technology With a Human Touch
The future of AI in clinical trials is likely to be less about replacing study teams and more about changing where they spend their time.
AI can review thousands of records faster than a person, surface possible matches, identify patterns, prioritize follow-up, and automate routine communication. People can do what those systems cannot reliably reproduce: listen to hesitation, recognize when someone is confused, explain what participation actually involves, adapt a conversation to individual circumstances, and escalate questions that require clinical expertise.
For recruitment teams, that can mean allowing technology to handle the first layer of scale while preserving live support at the moments that carry the greatest human consequence. A digital prescreener might identify a potentially eligible participant. AI might help determine which study appears relevant. Automated reminders might make follow-up more consistent. But when that person wants to understand what the study will mean for their daily life, a real conversation still has a distinct role.
Clinical research does not need to choose between efficiency and empathy. The more useful approach is to design workflows in which each does what it does best.
Keeping People at the Center of Clinical Research
AI will continue to expand what clinical trial teams can process, predict, and automate. Its value should be measured not simply by how many tasks it removes, but by whether it helps study teams make better use of human expertise and creates a clearer experience for participants.
The strongest approach to AI in clinical trials may therefore be a complementary one: technology for scale, analysis, and consistency, paired with people for judgment, trust, explanation, and support. In a field built around voluntary participation and complex healthcare decisions, innovation works best when the technology becomes more capable without making the experience less human.
This continuity becomes particularly important when something changes. A payer may request additional information. An authorization may be denied. A patient’s coverage may change. A specialty pharmacy may need clarification before dispensing. Follow-up gives the access team an opportunity to identify those issues while there is still a clear next action.
The broader direction of reimbursement administration also points toward greater workflow integration. CMS has finalized interoperability requirements intended to streamline prior authorization for many medical items and services, and in 2026 proposed extending similar electronic prior authorization capabilities to drugs covered under medical benefits. The proposal reflects the continuing industry focus on reducing fragmented documentation and improving the speed and transparency of authorization workflows.
For specialty therapies, the important lesson is that reimbursement is not one administrative event. It is a sequence of dependent steps. Reimbursement support services can help make those steps visible, organized, and connected so patients, providers, pharmacies, and support teams know what needs to happen next.
Practical Recommendations
For organizations designing or evaluating a reimbursement support model, three practices deserve particular attention:
Establish the coverage pathway early. Confirm the applicable benefit, payer requirements, authorization needs, and likely patient cost exposure before the case moves through multiple downstream teams. Early, accurate benefit identification as an opportunity to reduce duplication and delays.
Treat prior authorization and appeals as one continuous workflow. Build status tracking, documentation requirements, denial reasons, deadlines, and provider follow-up into the same case process rather than treating an appeal as an entirely new transaction. CMS’s prior authorization initiatives similarly emphasize better information exchange and greater process transparency.
Measure the handoffs, not only completed tasks. Track whether a patient successfully progresses from benefits investigation to authorization, affordability support, pharmacy coordination, and ultimately therapy start. Delays can arise at multiple points, including communication, authorization, formulary, financial assistance, and pharmacy fulfillment.